CHPA Responds to Nomination of Dr. Heidi Overton for FDA Commissioner

(WASHINGTON, D.C.) - Consumer Healthcare Products Association (CHPA) President & CEO Scott Melville released the below statement today following President Donald Trump's nomination of Dr. Heidi Overton to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA).

"The Consumer Healthcare Products Association (CHPA) welcomes the nomination of Dr. Heidi Overton to serve as Commissioner of the U.S. Food and Drug Administration.

Dr. Overton has extensive experience in medicine, public health, and health policy, and we are encouraged by expressed interest in expanding Rx-to-OTC switch opportunities, increasing consumer access to self-care options, and exploring ways to bring innovative healthcare products to market more efficiently. Her public support for policies that promote competition, affordability, transparency, and informed consumer decision-making reflects the important role self-care can play in helping Americans take greater control of their health.

We look forward to learning more about Dr. Overton's priorities as she moves through the confirmation process, and we are pleased the Administration is moving quickly to appoint a permanent leader of the FDA. Stable, science-based leadership is essential to a smooth-functioning FDA."

The Consumer Healthcare Products Association (CHPA), founded in 1881, is the national trade association representing the leading manufacturers and marketers of consumer healthcare products, including over-the-counter (OTC) medicines, dietary supplements, and OTC medical devices. CHPA is committed to empowering self-care by ensuring that Americans have access to products they can count on to be reliable, affordable, and convenient, while also delivering new and better ways to get and stay healthy. Visit www.chpa.org.